Navigation Links
Dual gene therapy suppresses lung cancer in preclinical test

Combination gene therapy delivered in lipid-based nanoparticles drastically reduces the number and size of human non-small cell lung cancer tumors in mice, researchers at The University of Texas M. D. Anderson Cancer Center and the University of Texas Southwestern Medical Center report in the Jan. 15 edition of Cancer Research.

Two tumor-suppressing genes given intravenously reduced cancer separately but had their most powerful effect when administered together, cutting the number of tumors per mouse by 75 percent and the weight of tumors by 80 percent.

"In cancer treatment we have combination chemotherapy, and we also combine different modes of therapy - surgery, radiation and chemotherapy. Now you've got the possibility of combined targeted gene therapy," said Jack Roth, M.D., professor and chair of the M. D. Anderson Department of Thoracic and Cardiovascular Surgery and a senior researcher on the project.

The genes wrapped in the nanoparticles were p53, a well-known tumor suppressor that works by causing defective cells to commit suicide and is often shut down or defective in cancer cells, and FUS1, a tumor-suppressor discovered by the research group that is deficient in most human lung cancers. Each nanoparticle carried one of the two genes.

The Cancer Research paper reports that FUS1 works with p53 to force the lung cancer cells to kill themselves - a process known as apoptosis.

Further analysis showed that the combination achieved greater cell suicide because FUS1 suppresses a gene that expresses a protein known to rapidly degrade p53, says senior author Lin Ji, Ph.D., M. D. Anderson associate professor of thoracic and cardiovascular surgery.

The FUS1/p53 combination also activates a cell suicide pathway based in the cells' mitochondria, their energy powerhouse.

Lab experiments first showed that the gene combination cut the number of viable cells in four lines of human non-small cell lung ca
'"/>

Source:University of Texas M. D. Anderson Cancer Center


Page: 1 2

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
(Date:12/4/2009)... model of heart cells, University of Iowa investigators have ... II (CaM kinase), disrupts the electrical activity of heart ... Columbia University, was published online Dec. 3 in the ... researchers have developed great interest in calmodulin kinase II ...
(Date:12/3/2009)... plant and animal species can be likened to emptying a ... potential medicines into the trash, or replacing every local cuisine ... their habitats may not just make the world boring. New ... risk for catching some nasty disease. , "Habitat destruction and ...
(Date:12/3/2009)... Rapids, Mich. (Dec. 3, 2009) Van Andel ... hormone abscisic acid (ABA) works at the molecular level to ... cold. Their findings, published in the journal Nature ... around the world and combat global food shortages. The ...
Breaking Biology News(10 mins):U-Iowa study helps advance heart-related research 2Species down, disease up 2Species down, disease up 3Species down, disease up 4VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3More Swine Flu Vaccine Coming Soon 60183 1More Swine Flu Vaccine Coming Soon 60183 2More Swine Flu Vaccine Coming Soon 60183 3Section 1803 3A Senate Health Care Bill Makes Planned Parenthood Quasi Government Agency 3F Asks ALL 60180 1Section 1803 3A Senate Health Care Bill Makes Planned Parenthood Quasi Government Agency 3F Asks ALL 60180 21 800 Therapist Announces New Executive Team and Tele Therapy Offering 60177 11 800 Therapist Announces New Executive Team and Tele Therapy Offering 60177 2
... Rochelle, NY, July 8, 2008Biotech and pharmaceutical firms ... to streamline the complicated drug discovery process, reports ... GEN ). Most successful approaches rely on a ... advanced data-analysis tools, according to an article in ...
... at the Biodesign Institute at Arizona State University have made ... biologically engineered organism that can effectively deliver an antigen in ... to use live salmonella bacterium as the containment/delivery method for ... forward in development of a new means of biological containment ...
... suitable carrier for an oral vaccine against Alzheimer,s disease, ... of Bioscience and Biotechnology (KRIBB) in Korea and colleagues ... Science at Wonkwang University. Although their research (1), just ... is still in the early stages, it is a ...
Other Biology News:From foe to friend: Researchers use salmonella as a way to administer vaccines in the body 2From foe to friend: Researchers use salmonella as a way to administer vaccines in the body 3From foe to friend: Researchers use salmonella as a way to administer vaccines in the body 4Can tomatoes carry the cure for Alzheimer's? 2
(Date:12/3/2009)... DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan ... Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at ... Delhi, India, November 22, 2009. Beike is China,s ... The conference, organized by ...
(Date:12/2/2009)... Dec. 2 Reportlinker.com announces that a ... its catalogue: ,, Carbondioxide Incubators - ... http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators are the ... cancer, research, and other applications for providing ...
(Date:12/2/2009)... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion ... trial of Cotara® in patients with relapsed glioblastoma multiforme ... is a targeted monoclonal antibody linked to a radioisotope ... Cotara specifically targets cells at the center of ...
(Date:12/2/2009)... Mass., Dec. 2 TechConnect World, an event ... product integration in cleantech, nanotech, biotech and MEMS, ... and business presentations. ,, Now in its 14th ... Science and Technology Institute (NSTI), and the Clean ...
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
... and assemble MOD® units, an innovative medication dispenser produced by Avancen ... ... 2009 -- Zeus, Inc., a global leader in the design and ... with Avancen MOD Corporation. Avancen produces the MOD (Medication on ...
... 13 On February 10, 2009, NeoStem, Inc. (NYSE ... NYSE Alternext US (the "Alternext") indicating that the Company ... Alternext Company Guide (the "Guide"), which requires a listed ... November 3, 2008, the Company had announced that it ...
... facility opening in Second Quarter,TORONTO, Feb. 13 /PRNewswire-FirstCall/ ... despite a challenging year for the biopharmaceutical industry, ... advance toward the ultimate goal of sustained profitability. ... quarter ended December 31, 2008. , In a ...
Other Biology Technology:Zeus Partners with Avancen MOD Corp. 2NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 3Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 4
... Glycine Transporter 2, Neuronal (GLYT2). The antiserum ... the central nervous system. The staining pattern ... described using in situ hybridization with probes ... been described for glycinergic neurons. Preabsorption of ...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide ... LIGHT. PACKAGED UNDER INERT GAS. A potent ... dose-dependent manner (K i = 1.7 ... Soluble in EtOH or DMSO. Unstable in ...
... Reacts with an early protein. ... 3 hours post-infection exhibiting an ... peak intensity between 6-24 hours. ... intense coarsely granular staining. ...
Biology Products: